{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:20:34Z","timestamp":1790875234444,"version":"4.1.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/bor.0b013e3283310d57","type":"journal-article","created":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T07:24:28Z","timestamp":1254381868000},"page":"636-641","source":"Crossref","is-referenced-by-count":38,"title":["Disease-modifying treatment in systemic sclerosis: current status"],"prefix":"10.1097","volume":"21","author":[{"given":"Niamh P","family":"Quillinan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.it.2005.09.002","article-title":"Targeted therapy comes of age in scleroderma","volume":"26","author":"Denton","year":"2005","journal-title":"Trends Immunol"},{"key":"R2-12-20210128","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/art.22721","article-title":"Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model","volume":"56","author":"Shand","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter prospective, randomised, double-blind, placebo controlled trial of corticosteroids and intravenous cyclophosphamide, followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R7-12-20210128","first-page":"298","article-title":"Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease","volume":"29","author":"Pakas","year":"2002","journal-title":"J Rheumatol"},{"key":"R8-12-20210128","first-page":"2371","article-title":"Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function","volume":"29","author":"Griffiths","year":"2002","journal-title":"J Rheumatol"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"R124","DOI":"10.1186\/ar2534","article-title":"Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomised controlled trials and observational prospective cohort studies","volume":"10","author":"Nannini","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0272989X08317015","article-title":"Oral cyclophosphamide for active scleroderma lung disease: a decision analysis","volume":"28","author":"Khanna","year":"2008","journal-title":"Med Decis Making"},{"key":"R11-12-20210128","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study","volume":"35","author":"Berezne","year":"2008","journal-title":"J Rheumatol"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/ken369","article-title":"A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide","volume":"48","author":"Sabnani","year":"2009","journal-title":"Rheumatology"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/40.1.84","article-title":"Pilot study of antithymocyte globulin plus mycophenolate mofetil in recent onset diffuse scleroderma","volume":"40","author":"Stratton","year":"2001","journal-title":"Rheumatology"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"Gerbino","year":"2008","journal-title":"Chest"},{"key":"R16-12-20210128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated and preserves lung function in patients with connective tissue disease related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomised double-blind trial, followed by a 24 week observational trial","volume":"35","author":"Van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"R18-12-20210128","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/art.21714","article-title":"A randomised, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"55","author":"Pope","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.071169","article-title":"Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma","volume":"36","author":"Johnson","year":"2009","journal-title":"J Rheumatol"},{"key":"R20-12-20210128","first-page":"613","article-title":"Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low-dose cyclophosphamide pulse therapy","volume":"25","author":"Paone","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadaskevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10067-004-0906-7","article-title":"Experience with azathioprine in systemic sclerosis associated with interstitial lung disease","volume":"23","author":"Dheda","year":"2004","journal-title":"Clin Rheumatol"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/1529-0131(200005)43:5<1054::AID-ANR14>3.0.CO;2-W","article-title":"Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen","volume":"43","author":"McKown","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.23501","article-title":"A multicenter, randomised, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis","volume":"58","author":"Postlethwaite","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/rheumatology\/36.3.390","article-title":"Blood and marrow stem cell transplants in autoimmune diseases: a consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT)","volume":"36","author":"Tyndall","year":"1997","journal-title":"Br J Rheumatol"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/ard.60.6.577","article-title":"Phase I\/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease","volume":"60","author":"Binks","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R27-12-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2003.011205","article-title":"Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT\/EULAR registry","volume":"63","author":"Farge","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R28-12-20210128","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study","volume":"110","author":"Nash","year":"2007","journal-title":"Blood"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2007.071464","article-title":"Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis","volume":"67","author":"Vonk","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s100670050158","article-title":"Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin: a preliminary report","volume":"19","author":"Levy","year":"2000","journal-title":"Clin Rheumatol"},{"key":"R31-12-20210128","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/ard.2006.060111","article-title":"Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study","volume":"66","author":"Nacci","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R33-12-20210128","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","article-title":"High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma","volume":"156","author":"Ihn","year":"2007","journal-title":"Br J Dermatol"},{"key":"R34-12-20210128","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/art.1780240903","article-title":"Plasmapheresis and immunosuppressive drug therapy in scleroderma","volume":"24","author":"Dau","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"R35-12-20210128","first-page":"81","article-title":"Clinical effectiveness of apheresis in the treatment of progressive systemic sclerosis","volume":"6","author":"Capodicasa","year":"1983","journal-title":"Int J Artif Organs"},{"key":"R36-12-20210128","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/03009748809105267","article-title":"Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis","volume":"17","author":"Akesson","year":"1988","journal-title":"Scandan J Rheumatol"},{"key":"R37-12-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/clin.1994.1024","article-title":"Immune modulation during the treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs","volume":"70","author":"Dau","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"R38-12-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","article-title":"Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects","volume":"28","author":"Szekanecz","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R39-12-20210128","first-page":"1636","article-title":"Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease","volume":"34","author":"Lam","year":"2007","journal-title":"J Rheumatol"},{"key":"R41-12-20210128","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/art.23645","article-title":"The controversial role of tumour necrosis factor \u03b1 in fibrotic diseases","volume":"58","author":"Distler","year":"2008","journal-title":"Arth Rheum"},{"key":"R43-12-20210128","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R44-12-20210128","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","article-title":"High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomised, controlled clinical trial","volume":"42","author":"Clements","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R45-12-20210128","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-2133.2008.08452.x","article-title":"A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset","volume":"158","author":"Derk","year":"2008","journal-title":"Br J Dermatol"},{"key":"R46-12-20210128","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-132-11-200006060-00004","article-title":"Recombinant human relaxin in the treatment of scleroderma: a randomised, double-blind, placebo-controlled trial","volume":"132","author":"Seibold","year":"2000","journal-title":"Ann Intern Med"},{"key":"R47-12-20210128","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/art.24380","article-title":"Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement. A randomised, double-blind, placebo-controlled trial","volume":"60","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R49-12-20210128","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1002\/art.23696","article-title":"Imatinib mesylate treatment of nephrogenic systemic fibrosis","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R50-12-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/j.ajkd.2008.08.029","article-title":"Imatinib in the treatment of nephrogenic systemic fibrosis","volume":"53","author":"Chandran","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R51-12-20210128","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/art.23648","article-title":"Is imatinib a promising drug in systemic sclerosis?","volume":"58","author":"van Daele","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R52-12-20210128","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/art.24221","article-title":"Molecular framework for response to imatinib mesylate in systemic sclerosis","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R53-12-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signalling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J"},{"key":"R54-12-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human ant-transforming growth factor \u03b21 antibody therapy in systemic sclerosis: a multicentre, randomised, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R55-12-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI12020","article-title":"Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients","volume":"108","author":"Stratton","year":"2001","journal-title":"J Clin Invest"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e3283310d57","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:59:10Z","timestamp":1620946750000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200911000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3283310d57","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}